"Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study"
When you participate in one of our programs, you are not just getting a prescription
Samples were sequenced on an Illumina MiSeq platform (PE250)
pmid:16413416 16
Across phase 2 programs in type 2 diabetes and in people with obesity without diabetes, orforglipron produced consistent HbA1c lowering and clinically relevant weight loss, with a gastrointestinal tolerability profile broadly similar to injectable GLP-1RA
Reduced Side Effects: Gastrointestinal problems, such as nausea, vomiting, diarrhea, and constipation, are less common at higher doses